{"entity":{"id":"chris-halloran","kind":"person","name":"Chris Halloran","aka":[],"tldr":"Liverpool pancreatic surgeon who leads EUROPAC, the UK registry and surveillance programme for families with inherited pancreatic cancer risk and hereditary pancreatitis.","summary":"Chris Halloran is Professor of Pancreatic Surgery at the University of Liverpool. His university page records a Liverpool medical degree (1994), FRCS (Eng) in 1998, research with Eithne Costello and John Neoptolemos on combination chemo-gene therapy for pancreatic cancer, recognition as a surgical trials methodologist, the European Pancreatic Club Gold Medal (2016) and an honorary FRCSEd (2024). He is clinical lead of EUROPAC, the European registry of familial pancreatic cancer and hereditary pancreatitis (ISRCTN62546421, sponsored by the University of Liverpool), whose scientific arm Europac-PLUS and surveillance arm Europac-PRIME study secondary screening; the 2026 European Journal of Cancer outcomes paper reports 893 individuals under UK surveillance since 2000. He was a co-author of ESPAC5.","asOf":"2026-09-24","links":[{"label":"University of Liverpool staff page","url":"https://www.liverpool.ac.uk/people/christopher-halloran"}],"tags":["pancreatic","surgeon","uk","surveillance"],"related":["bill-greenhalf","paula-ghaneh"],"cancers":["pancreatic"],"sections":["early-detection","surgery"],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["liverpool-hpb-centre"],"pathways":[],"terms":[],"trials":["europac","espac-5"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Professor of Pancreatic Surgery, University of Liverpool; Clinical Lead, EUROPAC","institutionId":"liverpool-hpb-centre","specialisms":["Pancreatic surgery","Familial pancreatic cancer surveillance","Surgical trial methodology","Acute pancreatitis"],"profiles":[{"label":"University of Liverpool staff page","url":"https://www.liverpool.ac.uk/people/christopher-halloran"}],"papers":[{"title":"Risk-stratified surveillance for individuals in the UK at high risk of developing pancreatic cancer: outcomes from the European Registry of Hereditary Pancreatic Diseases (EUROPAC)","journal":"European Journal of Cancer","year":2026,"doi":"10.1016/j.ejca.2026.116592"},{"title":"European Registry of Hereditary Pancreatic Diseases (EUROPAC): protocol for primary and secondary screening in individuals at high risk of pancreatic cancer","journal":"BMJ Open","year":2025,"doi":"10.1136/bmjopen-2025-100027"},{"title":"Immediate surgery compared with short-course neoadjuvant gemcitabine plus capecitabine, FOLFIRINOX, or chemoradiotherapy in patients with borderline resectable pancreatic cancer (ESPAC5)","journal":"Lancet Gastroenterology and Hepatology","year":2023,"doi":"10.1016/S2468-1253(22)00348-X"}]},"route":"/people/chris-halloran/","neighbours":{"person":[{"id":"bill-greenhalf","kind":"person","name":"Bill Greenhalf","route":"/people/bill-greenhalf/"},{"id":"paula-ghaneh","kind":"person","name":"Paula Ghaneh","route":"/people/paula-ghaneh/"}],"cancer":[{"id":"pancreatic","kind":"cancer","name":"Pancreatic ductal adenocarcinoma","route":"/cancers/pancreatic/"}],"section":[{"id":"early-detection","kind":"section","name":"Early Detection & Screening","route":"/fronts/early-detection/"},{"id":"surgery","kind":"section","name":"Surgery & Interventional","route":"/fronts/surgery/"}],"institution":[{"id":"liverpool-hpb-centre","kind":"institution","name":"Liverpool University Hospitals HPB centre (Aintree)","route":"/institutions/liverpool-hpb-centre/"}],"trial":[{"id":"espac-5","kind":"trial","name":"ESPAC-5","route":"/trials/espac-5/"},{"id":"europac","kind":"trial","name":"EUROPAC","route":"/trials/europac/"}]}}